TY - JOUR
T1 - Novel therapies and potential therapeutic targets in the management of chronic hepatitis B
AU - Serigado, Joao M.
AU - Izzy, Manhal
AU - Kalia, Harmit
N1 - Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc.
PY - 2017
Y1 - 2017
N2 - Chronic hepatitis B is a persistent and progressive inflammatory liver disease caused by infection with the hepatitis B virus (HBV). More than 240 million individuals are infected with HBV worldwide and hepatitis B accounts for an estimated 650 000 deaths annually. Approximately up to 30% of chronically infected patients will develop complications of HBV infection including, but not limited to, liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Currently approved therapies have improved clinical outcomes, but have a considerable side-effect profile, elevated cost, and a finite course of treatment. This has led to a growing interest in research for new therapies. As the mechanisms for HBV replication are becoming better understood, new potential targets have been discovered, leading to the development of new therapies. In this article, we describe the promising therapies that are under evaluation, showing their mechanisms of action, effects, and stage of development.
AB - Chronic hepatitis B is a persistent and progressive inflammatory liver disease caused by infection with the hepatitis B virus (HBV). More than 240 million individuals are infected with HBV worldwide and hepatitis B accounts for an estimated 650 000 deaths annually. Approximately up to 30% of chronically infected patients will develop complications of HBV infection including, but not limited to, liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Currently approved therapies have improved clinical outcomes, but have a considerable side-effect profile, elevated cost, and a finite course of treatment. This has led to a growing interest in research for new therapies. As the mechanisms for HBV replication are becoming better understood, new potential targets have been discovered, leading to the development of new therapies. In this article, we describe the promising therapies that are under evaluation, showing their mechanisms of action, effects, and stage of development.
KW - RNA interference
KW - covalently closed circular DNA
KW - hepatitis B virus
KW - novel therapies
KW - nucleoside analogues
KW - potential therapeutic targets
KW - therapeutic vaccines
KW - viral entry
KW - viral mechanisms
UR - http://www.scopus.com/inward/record.url?scp=85019543907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019543907&partnerID=8YFLogxK
U2 - 10.1097/MEG.0000000000000911
DO - 10.1097/MEG.0000000000000911
M3 - Review article
C2 - 28538269
AN - SCOPUS:85019543907
SN - 0954-691X
VL - 29
SP - 987
EP - 993
JO - European Journal of Gastroenterology and Hepatology
JF - European Journal of Gastroenterology and Hepatology
IS - 9
ER -